Articles

July 21, 2011 – The U.S. Food and Drug Administration (FDA) today approved AstraZeneca’s blood-thinning drug ticagrelor (Brilinta) to reduce cardiovascular death and heart attack in patients with...

April 7, 2011 – New study results have evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on clopidogrel (Plavix). The results showed that in healthy subjects,...

Clopidogrel (Plavix) has been the standard antiplatelet therapy for a decade, but it is now facing challenges with the fact that one-third of patients do not respond to the agent and new drugs...

December 29, 2010 - Research on reducing risks, improving medical treatment and improving lifestyle behaviors to fight the battle against heart disease and stroke are among the key scientific...

For patients with severe hypertension that remains uncontrolled despite medical therapy, radiofrequency (RF) energy can be used in the renal vessels to block nerves involved with the sympathetic...

A new class of antiplatelet therapy drug pending U.S. Food and Drug Administration (FDA) clearance may offer greater benefits over clopidogrel (Plavix) the current standard of therapy. The new...

March 18, 2010 – The U.S. Food and Drug Administration (FDA) today added a boxed warning to the anti-blood clotting drug Plavix (clopidogrel), alerting patients and healthcare professionals that...

March 17, 2010 – New Results from PLATO trial suggest ticagrelor (Brilinta) leads to lower mortality and no increased risk of bleeding when compared to clopidogrel (Plavix) in patients with acute...

March 16, 2010 — Lowering blood pressure to normal levels — below currently recommended levels — did not significantly reduce the combined risk of fatal or nonfatal cardiovascular disease events...

March 3, 2010 – Pharmaceutical companies will struggle to profit from the cardiovascular disease (CVD) market over the next decade despite growing drug usage, according to new market research from...